Unmasking deep-rooted trauma: long-term effects of childhood adversities on posttraumatic stress disorder in healthcare workers facing acute multi-trauma
How stressful life events are associated with depression: the mediating pathway of security in a clinical adolescent sample
Medical evaluation of first presentation of psychotic symptoms in children and adolescents
Self images: an empirical enquiry into Rembrandt’s self-portraits
Fast and accurate multiple-protein-sequence alignment at scale with FAMSA2
Nature Biotechnology, Published online: 14 April 2026; doi:10.1038/s41587-026-03095-3
FAMSA2 accurately aligns millions of protein sequences at high speed.
Editorial Expression of Concern: Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions
Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04390-x
Editorial Expression of Concern: Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions
The gut microbiome as a fingerprint of antibiotic use history
Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04360-3
Antibiotic use over the past 8 years was associated with alterations in the gut microbiome composition in 14,979 individuals. These analyses integrated data from the Swedish National Prescribed Drug Register and stool metagenomic profiles. Alterations were found even after a single antibiotic course and varied markedly across different antibiotic classes.
Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial
Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04317-6
A first-in-human phase 1 trial shows that intravitreal photoswitch therapy can be administered safely in advanced retinitis pigmentosa, with exploratory signals compatible with light responsiveness following treatment.
Antisense oligonucleotide-mediated knockdown therapy in two infants with severe KCNT1 epileptic encephalopathy
Nature Medicine, Published online: 14 April 2026; doi:10.1038/s41591-026-04314-9
Two individuals with KCNT1-related epileptic encephalopathy were treated with a KCNT1-targeting antisense oligonucleotide, leading to significant reductions in seizure frequency and intensity, but also the development of hydrocephalus.

